Leerink Partners Maintains Outperform on Teva Pharmaceutical Indus, Raises Price Target to $52

Benzinga · 4d ago
Leerink Partners analyst Daniel Clark maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Outperform and raises the price target from $45 to $52.